Clinical trials: Obese Subjects
Obesity
The ValenTx Endo Bypass System in Obese Subjects
The purpose of this study is to collect clinical data to support the use of the ValenTx Endo Bypass System to improve weight loss and the resolution of comorbidities in obese subjects.
- Trial name
- NCT02954003
- Testing
- Endo Bypass System
- Where
- 3 sites in Canada, Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- ValenTx, Inc.
Overweight, Obesity
Effect of GSP3 on Body Weight in Overweight and Obese Subjects
The FLOW (First Loss Of Weight) study is designed to assess the effects of repeated administration of GSP3, an investigational product, on body weight.
- Trial name
- FLOW (NCT03008954)
- Testing
- GSP3, Avicel (modified Cellulose)
- Where
- 5 sites in Czechia, Denmark and 1 more
- Volunteers
- 128 people
- Sponsor
- Gelesis, Inc.
Obesity, Nutritional and Metabolic Diseases
A Study of the Safety of R256918 in Obese Patients
This study investigates the safety of 12 weeks of treatment with R256918, in obese patients (JNJ-16269110 and R256918 are different names for the same molecule).
- Conditions
- Obesity, Nutritional and Metabolic Diseases, Metabolic Diseases, Nutrition Disorders
- Trial name
- NCT01041677
- Testing
- R256918
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 71 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity
Study of Obese Subjects Previously Implanted With the EndoBarrier Gastrointestinal Liner
The purpose of this study is to determine whether the GI Endobarrier Liner can be reimplanted.
- Trial name
- NCT01372501
- Testing
- Endobarrier Liner
- Where
- Chile
- Volunteers
- 19 people
- Sponsor
- Morphic Medical Inc.
Inflammatory Bowel Diseases
First Time in Human Study of Intravenous Interleukin-18 Antibody
GSK1070806 is a humanised monoclonal antibody that blocks a protein present in the body called Interleukin-18. The main purpose of this study is to test GSK1070806 in healthy and obese male subjects with normal immune systems to…
- Trial name
- A18110040 (NCT01035645)
- Testing
- GSK1070806
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy, Non-diabetic Overweight or Obese
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects
A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese…
- Trial name
- NCT07239973
- Testing
- BGM0504 tablets
- Where
- China
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Overweight and Obesity
A Phase I Study of GZR18 Injection in Obese/Overweight Subjects
This is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical study. A sequential design is used in this trial with a single dose escalation climb test, to investigate the safety, tolerability, and…
- Trial name
- NCT06548945
- Testing
- GZR18
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 2 Diabetes, Diabetes Mellitus, Type 2
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation…
- Conditions
- Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases
- Trial name
- NCT01474161
- Testing
- GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation
- Where
- France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Genfit
Obesity
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat.
- Trial name
- NCT04081337
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Overweight and Obesity
Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .
The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in Chinese Obese Subjects.
- Trial name
- NCT06250946
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Metabolism and Nutrition Disorder, Obesity
Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for…
- Trial name
- NCT02870231
- Testing
- NNC9204-0530, liraglutide
- Where
- 2 sites in United States
- Volunteers
- 187 people
- Sponsor
- Novo Nordisk A/S
Insulin Resistance
Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects
The objectives of this study are to evaluate the safety, tolerance and pharmacokinetics of HE3286 when administered daily for 28 days to obese adult subjects and to assess potential activity of HE3286 to decrease insulin…
- Trial name
- NCT00555451
- Testing
- HE3286
- Where
- 2 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Harbor Therapeutics
Pharmacokinetics in Obese Adolescents
Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age
The purpose of this study is to evaluate the PK properties, tolerability, and safety of lorcaserin HCL (BELVIQ) in obese adolescent subjects between the ages of 12 to 17 years old
- Trial name
- NCT02022956
- Testing
- Lorcaserin
- Where
- 2 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Obesity
To Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects
To Evaluate the safety, tolerability and pharmacokinetic property after KD101 multiple oral dosing in the fed state in obese or overweight subjects.
- Trial name
- NCT02462031
- Testing
- KD101
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Overweight and Obesity
A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of continuous oral administration of DA-302168S tablets for 28 days in overweight/obese subjects.
- Trial name
- DA168 (NCT06541730)
- Testing
- DA-302168S
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.
Obesity/Overweight
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function
This study adopts a multicenter, single-dose, open-label, and parallel design, which is aimed at assessing the PK and safety profiles of GZR18 Injection in subjects with normal renal function and those with mild, moderate or…
- Trial name
- NCT07141030
- Testing
- GZR18 injection
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Obesity
Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects
The purpose of this study is to evaluate the PK properties of lorcaserin in obese or overweight elderly subjects.
- Trial name
- NCT00828581
- Testing
- lorcaserin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Eisai Inc.
Obesity, Overweight
A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes
The purpose of this study is determine whether the combination of naltrexone SR and bupropion SR is safe and effective in treating obesity in subjects with type 2 diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT00474630
- Testing
- Naltrexone SR 32 mg/bupropion SR 360 mg/ day, Ancillary therapy
- Where
- 53 sites in United States
- Volunteers
- 505 people
- Sponsor
- Orexigen Therapeutics, Inc
Morbid Obesity
Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band
The purpose of the study is to evaluate the long term safety of the Swedish Adjustable Gastric Band (SAGB) in subjects with an SAGB in place.
- Trial name
- SAGB-PM (NCT00543140)
- Testing
- REALIZE™ Swedish Adjustable Gastric Band
- Where
- 8 sites in United States
- Volunteers
- 303 people
- Sponsor
- Ethicon Endo-Surgery
Overweight and Obesity
Extension Study of Gelesis100 on Body Weight
This study is designed to assess the effect of Gelesis100 on body weight after an additional exposure of 24 weeks in subjects who completed the 24-week treatment period, and had at least 3% weight loss, in the Gelesis Loss Of…
- Trial name
- GLOW-EX (NCT03021291)
- Testing
- Gelesis100 (2.25 g)
- Where
- 16 sites in United States, Czechia and 3 more
- Volunteers
- 36 people
- Sponsor
- Gelesis, Inc.